Antiviral activity of ganciclovir elaidic acid ester against herpesviruses

Antiviral Research

Volumn 45, Issue 3, 2000, Pages 157-167

  Andrei, Graciela ^a   Snoeck, Robert ^a   Neyts, Johan ^a   Sandvold, Marit Liland ^b   Myhren, Finn ^b   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b STATOIL   (Norway)

Author keywords

Ganciclovir elaidic ester; HSV; Prodrug

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; CIDOFOVIR; ELAIDIC ACID; FOSCARNET; GANCICLOVIR; GANCICLOVIR DERIVATIVE; GANCICLOVIR ELAIDIC ACID ESTER; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BRAIN INFECTION; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IC 50; LUNG FIBROBLAST; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

ACYCLOVIR; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BROMODEOXYURIDINE; CELL LINE; CYTOMEGALOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; FOSCARNET; GANCICLOVIR; HERPESVIRUS 3, HUMAN; HIV-1; HIV-2; HUMANS; MICE; SIMPLEXVIRUS;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 5;

EID: 0034163622     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00070-X     Document Type: Article

References (38)

1. Agut H., Huraux J.M., Collandre H., Montagnier L. Susceptibility of human herpesvirus 6 to acyclovir and ganciclovir. Lancet. 2:1989;626.
2. Alford C.A., Britt W.J. Cytomegaloviruses. Roizman B., Whitley R.J., Lopez C. The Human Herpesvirus. 1993;227-255 Raven Press, New York.
3. Andrei G., Snoeck R., De Clercq E. Susceptibility of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds. Antimicrob. Agents Chemother. 39:1995;1632-1635.
4. Ashton W.T., Karkas J.D., Field A.K., Tolman R.L. Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG). Biochem. Biophys. Res. Commun. 108:1982;1716-1721.
5. Balzarini J., Bohman C., Walker R.T., De Clercq E. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol. Pharmacol. 45:1994;1253-1258.
6. Balzarini J., Degrève B., Andrei G., Neyts J., Sandvold M., Myhren F., De Clercq E. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. Gene Ther. 5:1998;419-426.
7. Biron K.K., Stanat S.C., Sorrell J.B., Fyfe J.A., Keller P.M., Lambe C.U., Nelson D.J. Metabolic activation of the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl)guaninein human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA. 82:1985;2473-2477.
8. Borelli E., Heyman R., His M., Evans R.M. Targetting of an inducible toxic phenotype in animals cells. Proc. Natl. Acad. Sci. USA. 85:1988;7572-7576.
9. Cheng Y.-C., Huang E.-S., Lin J.-C., Mar E.-C., Pagano J.S., Dutschman G.E., Grill S.P. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA. 80:1983;2767-2770.
10. Cheng Y.C., Grill S.P., Dutschman G.E., Nakayam K., Bastow K.F. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J. Biol. Chem. 258:1983;12460-12464.
11. Corey, L., Spear, P.G., 1986. Infections with herpes simplex viruses. New Engl. J. Med. 314, 686-691 & 749-757.
12. Crumpacker C.S. Ganciclovir. New Engl. J. Med. 335:1996;721-729.
13. Crumpacker C.S., Kowalsky P.N., Oliver S.A., Schnipper L.E., Field A.K. Resistance of herpes simplex virus to 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus. Proc. Natl. Acad. Sci. USA. 81:1984;1556-1560.
14. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1992;1550-1552.
15. Culver K.W., Van Gilder J., Link C.J., Carlstrom T., Buroker T., Yuh W., Koch K., Schabold K., Doornbas S., Wetjen B. et al. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5:1994;343-379.
16. Descamps J., De Clercq E. Specific phosphorylation of E-5-(2-iodovinyl)-2′-deoxyuridine by herpes simplex virus-infected mice. J. Biol. Chem. 256:1981;5973-5976.
17. Drew W.L., Miner R.C., Busch D.F., Follansbee S.E., Gullett J., Mehalko S.G., Gordon S.M., Owen W.F. Jr, Matthews T.R., Buhles W.C., DeArmond B. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:1991;716-719.
18. Erice A., Chou S., Biron K.K., Stanat S.C., Balfour H.H. Jr, Jordan M.C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. New Engl. J. Med. 320:1989;289-293.
19. Field A.K., Davies M.E., DeWitt C., Perry H.C., Liou R., Germershausen J., Karkas J.D., Ashton W.T., Johnston D.B.R., Tolman R.L. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. USA. 80:1983;4139-4143.
20. Frank K.B., Chiou J.-F., Cheng Y.-C. Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J. Biol. Chem. 259:1984;1566-1569.
21. Germershausen J., Bostedor R., Field A.K., Perry H., Liou R., Bull H., Tolman R.L., Karkas J.D. A comparison of the antiviral agents 2′-nor-2′-deoxyguanosine and acyclovir; uptake and phosphorylation in tissue culture and kinetics of in vitro inhibition of viral and cellular DNA polymerases by their respective triphosphates. Biochem. Biophys. Res. Commun. 116:1983;360-367.
22. Jennings R., Smith T.L., Myhren F., Phillips J., Sandvold M.L. Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes. Antimicrob. Agents Chemother. 43:1999;53-61.
23. Kun L.E., Gajjar A., Muhlbauer M., Heideman R.L., Sanford R., Brenner M., Walter A., Langston J., Jenkins J., Facchini S. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum. Gene Ther. 6:1995;1231-1255.
24. Lin J.C., Smith M.C., Pagano J.S. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J. Virol. 50:1984;50-55.
25. Littler E., Stuart A.D., Chee M.S. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature. 358:1992;160-162.
26. Mar E.C., Chiou J.F., Cheng Y.C., Huang E.S. Inhibition of cellular DNA polymerase ( and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Virol. 53:1985;776-780.
27. Martin J.C., Dvorak C.A., Smee D.F., Matthews T.R., Verheyden J.P.H. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J. Med. Chem. 26:1983;759-761.
28. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46:1986;5276-5281.
29. Noble S., Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 56:1998;115-146.
30. Raffel C., Culver K., Kohn D., Nelson M., Siegel S., Gillis F., Link C.J., Villblanca J.G., Anderson W.F. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5:1994;863-890.
31. Safrin S., Ashley R., Houlihan C., Cusick P.S., Mills J. Clinical and serologic features of herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. J. AIDS. 5:1991;1107-1110.
32. Smee D.F., Boehme R., Chernow M., Binko B.P., Matthews T.R. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem. Pharmacol. 34:1985;1049-1056.
33. Smith K.O., Galloway K.S., Kennell W.L., Ogilvie K.K., Radatus B.K. A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. 22:1982;55-61.
34. Snoeck R., Andrei G., Gérard M., Silverman A., Hedderman A., Balzarini J., Sadzot-Delvaux C., Tricot G., Clumeck N., De Clercq E. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin. Infect. Dis. 18:1994;570-578.
35. Stanat S.C., Reardon J.E., Erice A., Jordan M.C., Drew W.L., Biron K.K. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob. Agents Chemother. 35:1991;2191-2197.
36. Sullivan V., Talarico C.L., Stanat S.C., Davis M., Coen D.M., Biron K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature. 358:1992;162-164.
37. Weller T.H. Varicella and herpes zoster: a perspective and overview. J. Infect. Dis. 166(Suppl. 1):1992;1-16.
38. Wutlzer P. Antiviral therapy of herpes simplex and varicella zoster virus infections. Intervirology. 40(5-6):1997;343-356.